Azitra Inc

Azitra Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for skin diseases using precision dermatology. They specialize in genetically engineered bacteria, particularly strains of Staphylococcus epidermidis, for therapeutic use. Their approach combines a proprietary microbial library of over 1,500 unique bacterial strains with advanced genetic engineering techniques and artificial intelligence to identify and create new therapeutic products. Azitra's pipeline currently includes two live biotherapeutic product candidates and one protein candidate, with a focus on treating conditions like Netherton syndrome, cancer therapy-associated rash, and ichthyosis vulgaris.

The company leverages the natural benefits of skin commensal bacteria, their ability to interact with the immune system, and their potential to deliver therapeutic proteins directly to the skin. Azitra is committed to expanding its capabilities through partnerships and collaborations with leading research institutions like Carnegie Mellon University and the Fred Hutchinson Cancer Center. Their research and development efforts are focused on creating safe and effective treatments that address the unmet needs of patients suffering from various skin conditions.

Azitra is a clinical-stage biopharmaceutical company focused on precision dermatology, using engineered proteins and live biotherapeutic products to treat skin diseases. They are developing novel therapeutics by leveraging their extensive knowledge of genetic engineering, proteomics, and the skin microbiome. Azitra's mission is to create new treatments for adverse skin conditions and diseases by harnessing the power of microbial and genetic engineering.

Azitra promotes a culture of innovation and collaboration, driven by a team of scientists and researchers focused on developing precision dermatology treatments. The company values scientific excellence, a commitment to patient well-being, and a collaborative approach to research. The company’s culture is characterized by a dedication to leveraging cutting-edge technologies like microbial and genetic engineering to address unmet needs in dermatology.